Nasus Pharma Prepares for $11 Million U.S. IPO: Intranasal Drugmaker Aims for Market Entry with Epinephrine Powder Technology
An Israeli biotech firm with emergency care ambitions takes its case to Wall Street
Tel Aviv-based Nasus Pharma is moving forward with its U.S. public debut, targeting...
Highview Merger SPAC Files for $200M IPO: A Strategic Bid for Middle-Market Dominance
A fresh entrant with experienced leadership and focused M&A strategy hits the Nasdaq under HVMCU
In a market still weighing the merits of blank-check firms,...